We propose an effective administration model using organizational structure for a decentralized role-based access control environment. Access control administration is a critical issue for large organizations and information systems. A large organization needs decentralized access control by multiple security officers because it has many users and information objects, and a single security offi...

Information about drugs undergoing the regulatory approval process in Canada is shrouded in secrecy. The Health Protection Branch (HPB) of Health Canada considers confidential the information submitted by a manufacturer in requesting approval for a drug and at present does not publicly disclose that a product is under review. (In April 1998, the HPB proposed to list products under review on its...

For the last several years, there have been a decreasing number of new innovative medical therapies approved for use in the United States despite an increasing expenditure on medical product development. This situation has been compounded by an increasing awareness of safety issues arising from these approved drugs as well as frommedical devices that have resulted in medical product discontinua...

Funding from the Centers for Disease Control and Prevention and the Health Resources and Services Administration (HRSA) supports collaborations among health departments (CA, FL, GA, IL, MA, NJ, NY), correctional facilities, and community-based organizations to improve services to HIV-infected inmates, particularly as they return to the community. Additionally, HRSA funded the Evaluation and Pro...

This editorial introduces the F1000Research rare disease collection. It is common knowledge that for new treatments to be successful there has to be a partnership between the many interested parties such as the patient, advocate, disease foundations, the academic scientists, venture funding organizations, biotech companies, pharmaceutical companies, NIH, and the FDA. Our intention is to provide...

FDA in the 21st Century is an excellent edited volume based on the Petrie–Flom Center’s1 2013 Annual Conference.2 The conference sought to gather thought leaders in academia, government, and private industry to evaluate the Agency and to make recommendations for Food andDrug Administration’s (FDA’s) future functioning. Peter Barton Hutt referred to it as, ‘unquestionably the largest, comprehens...

Volatile Organic Compound (VOC) measurements in the Pearl River Delta (PRD) region, China Y. Liu, M. Shao, S. H. Lu, C.-C. Chang, J.-L. Wang, and G. Chen State Joint Key Laboratory of Environmental Simulation and Pollution Control, College of Environmental Sciences and Engineering, Peking University, Beijing, China Res. Center of Environment Change, Academia Sinica, Nankang, Taipei 115, Taiwan,...

The discovery of effective cancer treatments is a key goal for pharmaceutical companies. However, the current costs of bringing a cancer drug to the market in the USA is now estimated at $1 billion per FDA approved drug, with many months of research at the bench and costly clinical trials. A growing number of papers highlight the use of data mining tools to determine associations between drugs,...

The Filovirus Animal Non-Clinical Group (FANG) is a US interdepartmental and interagency group established to support and facilitate the advanced development of filovirus Medical Countermeasures (MCM), both vaccines and therapeutics. It is co-led by one representative from the Department of Defense (DoD), the first author, and one from the Department of Health and Human Services (HHS), the seco...